© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
June 01, 2014
Experts examine conflicting evidence regarding the continuation of disease-modifying therapy in patients with secondary progressive multiple sclerosis.
Session at the 2014 Annual Meeting of the Consortium of Multiple Sclerosis Centers debates whether the side effects associated with alemtuzumab, a novel anti-CD52 monoclonal antibody, might ultimately prevent its approval for the treatment of multiple sclerosis, despite evidence of clinical effectiveness.
May 31, 2014
Low rates of immunogenicity observed in study support the potential benefits of subcutaneous peginterferon beta-1a in the treatment of patients with relapsing-remitting multiple sclerosis.
The reductions in brain volume often seen in patients with chronic relapsingâ€“remitting multiple sclerosis may be reduced by treatment with interferon beta-1a, though treatment may be affected by the patient's immunologic status.
Atopic Dermatitis Severity Linked to Incremental Societal Healthcare Costs
Strong Response Maintenance for Plaque Psoriasis Patients Using Tildrakizumab
Clinical Efficacy, Safety of Brolucizumab Similar to Trial Results for nAMD Patients